{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:44:41Z","timestamp":1786985081071,"version":"build-2736575974"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100002081","name":"Irish Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002081","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014364","name":"National Children's Research Centre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014364","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001590","name":"Health Research Board","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001590","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006312","name":"BrightFocus Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006312","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001602","name":"Science Foundation Ireland","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001602","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1016\/j.bcp.2019.04.029","type":"journal-article","created":{"date-parts":[[2019,4,27]],"date-time":"2019-04-27T03:04:15Z","timestamp":1556334255000},"page":"321-325","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":36,"special_numbering":"C","title":["Current perspectives on established and novel therapies for pathological neovascularization in retinal disease"],"prefix":"10.1016","volume":"164","author":[{"given":"Matthew","family":"Campbell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6294-9380","authenticated-orcid":false,"given":"Sarah L","family":"Doyle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcp.2019.04.029_b0005","doi-asserted-by":"crossref","first-page":"2955","DOI":"10.1002\/eji.200425327","article-title":"Mini-review: transendothelial migration of leukocytes: through the front door or around the side of the house?","volume":"34","author":"Engelhardt","year":"2004","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.bcp.2019.04.029_b0010","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1038\/nature03987","article-title":"Pathophysiological consequences of VEGF-induced vascular permeability","volume":"437","author":"Weis","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2019.04.029_b0015","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/nature10144","article-title":"Molecular mechanisms and clinical applications of angiogenesis","volume":"473","author":"Carmeliet","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2019.04.029_b0020","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/383073a0","article-title":"Role of tissue factor in embryonic blood vessel development","volume":"383","author":"Carmeliet","year":"1996","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2019.04.029_b0025","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1038\/380439a0","article-title":"Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene","volume":"380","author":"Ferrara","year":"1996","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2019.04.029_b0030","doi-asserted-by":"crossref","first-page":"428","DOI":"10.4103\/0301-4738.100542","article-title":"The worldwide epidemic of diabetic retinopathy","volume":"60","author":"Zheng","year":"2012","journal-title":"Indian J. Ophthalmol."},{"key":"10.1016\/j.bcp.2019.04.029_b0035","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S0140-6736(97)04195-0","article-title":"Diabetic eye disease","volume":"350","author":"Klein","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/j.bcp.2019.04.029_b0040","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1007\/s11892-014-0573-2","article-title":"From pathobiology to the targeting of pericytes for the treatment of diabetic retinopathy","volume":"15","author":"Arboleda-Velasquez","year":"2015","journal-title":"Curr Diab Rep."},{"key":"10.1016\/j.bcp.2019.04.029_b0045","doi-asserted-by":"crossref","first-page":"e106","DOI":"10.1016\/S2214-109X(13)70145-1","article-title":"Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis","volume":"2","author":"Wong","year":"2014","journal-title":"Lancet Glob Health."},{"key":"10.1016\/j.bcp.2019.04.029_b0050","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1016\/S0140-6736(10)60484-9","article-title":"Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies","volume":"375","author":"Emerging Risk Factors","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.bcp.2019.04.029_b0055","doi-asserted-by":"crossref","first-page":"2606","DOI":"10.1056\/NEJMra0801537","article-title":"Age-related macular degeneration","volume":"358","author":"Jager","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bcp.2019.04.029_b0060","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1038\/eye.2014.141","article-title":"25th RCOphth Congress, President's Session paper: 25 years of progress in medical retina","volume":"28","author":"Gibson","year":"2014","journal-title":"Eye (Lond)."},{"key":"10.1016\/j.bcp.2019.04.029_b0065","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1056\/NEJM197111182852108","article-title":"Tumor angiogenesis: therapeutic implications","volume":"285","author":"Folkman","year":"1971","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bcp.2019.04.029_b0070","doi-asserted-by":"crossref","first-page":"5836","DOI":"10.1167\/iovs.18-25307","article-title":"Functional characterization of Abicipar-Pegol, an anti-VEGF DARPin therapeutic that potently inhibits angiogenesis and vascular permeability","volume":"59","author":"Rodrigues","year":"2018","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.bcp.2019.04.029_b0075","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/S0140-6736(17)30979-0","article-title":"Intravitreous injection of AAV2-sFLT01 in patients with advanced neovascular age-related macular degeneration: a phase 1, open-label trial","volume":"390","author":"Heier","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.bcp.2019.04.029_b0080","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1016\/j.ophtha.2013.03.046","article-title":"Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP)","volume":"120","author":"Rofagha","year":"2013","journal-title":"Ophthalmology"},{"key":"10.1016\/j.bcp.2019.04.029_b0085","first-page":"1857","article-title":"Resistance to anti-VEGF therapy in neovascular age-related macular degeneration: a comprehensive review","volume":"10","author":"Yang","year":"2016","journal-title":"Drug Des. Dev. Ther."},{"key":"10.1016\/j.bcp.2019.04.029_b0090","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1038\/eye.2014.64","article-title":"Switch of anti-VEGF agents is an option for nonresponders in the treatment of AMD","volume":"28","author":"Ehlken","year":"2014","journal-title":"Eye (Lond)."},{"key":"10.1016\/j.bcp.2019.04.029_b0095","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1002\/jcp.24575","article-title":"Interleukin-18 has antipermeablity and antiangiogenic activities in the eye: reciprocal suppression with VEGF","volume":"229","author":"Shen","year":"2014","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.bcp.2019.04.029_b0100","doi-asserted-by":"crossref","first-page":"230ra44","DOI":"10.1126\/scitranslmed.3007616","article-title":"IL-18 attenuates experimental choroidal neovascularization as a potential therapy for wet age-related macular degeneration","volume":"6","author":"Doyle","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.bcp.2019.04.029_b0105","doi-asserted-by":"crossref","first-page":"5424","DOI":"10.1167\/iovs.15-17264","article-title":"IL-18 immunotherapy for neovascular AMD: tolerability and efficacy in nonhuman primates","volume":"56","author":"Doyle","year":"2015","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.bcp.2019.04.029_b0110","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1096\/fasebj.13.15.2195","article-title":"Interleukin-18 acts as an angiogenesis and tumor suppressor","volume":"13","author":"Cao","year":"1999","journal-title":"FASEB J."},{"key":"10.1016\/j.bcp.2019.04.029_b0115","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1016\/j.ajpath.2015.04.013","article-title":"IL-4 regulates specific Arg-1(+) macrophage sFlt-1-mediated inhibition of angiogenesis","volume":"185","author":"Wu","year":"2015","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.bcp.2019.04.029_b0120","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1002\/path.4816","article-title":"Interleukin-33 regulates tissue remodelling and inhibits angiogenesis in the eye","volume":"241","author":"Theodoropoulou","year":"2017","journal-title":"J. Pathol."}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295219301649?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295219301649?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T15:04:00Z","timestamp":1762095840000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295219301649"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6]]},"references-count":24,"alternative-id":["S0006295219301649"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2019.04.029","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2019,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Current perspectives on established and novel therapies for pathological neovascularization in retinal disease","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2019.04.029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}